MBX Biosciences Reports Positive One-Year Trial Results for Hypoparathyroidism Treatment

MBX Biosciences has released encouraging one-year data for its experimental drug, canvuparatide, in treating chronic hypoparathyroidism. The results indicate sustained benefits, with over half of patients responding to the once-weekly therapy in an open-label extension study. The company plans to further discuss these findings in an upcoming conference call.